These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Efavirenz: new preparation. An alternative to HIV protease inhibitors. Prescrire Int; 2000 Apr; 9(46):46-9. PubMed ID: 11503786 [TBL] [Abstract][Full Text] [Related]
46. On the road with protease inhibitors. Cadman J GMHC Treat Issues; 1998 May; 12(5):10-2. PubMed ID: 11365475 [TBL] [Abstract][Full Text] [Related]
47. Once-daily therapies. Carey D J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708 [TBL] [Abstract][Full Text] [Related]
48. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R; AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336 [TBL] [Abstract][Full Text] [Related]
51. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
52. Merck announces compassionate-treatment lottery for Crixivan. J Int Assoc Physicians AIDS Care; 1995 Jul; 1(6):38. PubMed ID: 11362730 [TBL] [Abstract][Full Text] [Related]
53. Choosing the right initial antiretroviral regimens. Norton M GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117 [TBL] [Abstract][Full Text] [Related]
54. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Wasmuth JC; la Porte CJ; Schneider K; Burger DM; Rockstroh JK Antivir Ther; 2004 Apr; 9(2):213-20. PubMed ID: 15134183 [TBL] [Abstract][Full Text] [Related]
55. A review of low-dose ritonavir in protease inhibitor combination therapy. Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760 [TBL] [Abstract][Full Text] [Related]
56. Salvage therapy for Indinavir and Ritonavir users. TreatmentUpdate; 1999 Jul; 11(5):1-2. PubMed ID: 11366926 [TBL] [Abstract][Full Text] [Related]
57. Saquinavir switch study stopped. Treat Rev; 1997 Apr; (No 24):6. PubMed ID: 11364285 [TBL] [Abstract][Full Text] [Related]
58. Indinavir (Crixivan) access and distribution. James JS AIDS Treat News; 1996 Apr; (no 244):3-5. PubMed ID: 11363304 [TBL] [Abstract][Full Text] [Related]
59. American Dietetic Association's additional food list for indinavir. BETA; 1997 Sep; ():17, 22. PubMed ID: 11364693 [TBL] [Abstract][Full Text] [Related]